Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

CNBC’s Angelica Peebles and Novo Nordisk CEO Lars Fruergaard Jørgensen join 'Squawk Box' to discuss the company's quarterly ...

GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...

Lee Kindlon believes the previous district attorney, who had been in office for 20 years, was full of excuses on why things ...

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose ...